SCHEMBL25656402

SCHEMBL25656402

CCc1cc2scnc2cc1C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 2/20 0.36
PKM P14618 1/20 0.36
KDM4E B2RXH2 2/20 0.36
HKDC1 Q2TB90 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NTRK1 P04629 1/20 0.33
NTRK2 Q16620 1/20 0.33
HSD17B10 Q99714 1/20 0.32
IRAK4 Q9NWZ3 2/20 0.32
FFAR1 O14842 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24447316 0.93 TAS1R3 (0.38) TAS1R3TAS1R1NPC1RAB9AMEN1
SCHEMBL15912333 0.82 ALDH1A1 (0.39) TAS1R3TAS1R1NPC1RAB9AMEN1
SCHEMBL13311451 0.82 NPC1 (0.42) TAS1R3TAS1R1NPC1RAB9AMEN1
SCHEMBL24932464 0.77 ALDH1A1 (0.35) TAS1R3TAS1R1NPC1RAB9AMEN1
SCHEMBL8980389 0.77 NPC1 (0.41) TAS1R3TAS1R1NPC1RAB9AMEN1
SCHEMBL24253408 0.76 LMNA (0.38) TAS1R3TAS1R1NPC1RAB9AALDH1A1
SCHEMBL24984324 0.76 TGFBR1 (0.35) TAS1R3TAS1R1NPC1RAB9AMEN1
SCHEMBL21025996 0.76 NPC1 (0.39) TAS1R3TAS1R1NPC1RAB9AMEN1
SCHEMBL6298458 0.76 ALDH1A1 (0.34) TAS1R3TAS1R1NPC1RAB9AALDH1A1
SCHEMBL24611377 0.75 ALDH1A1 (0.33) TAS1R3TAS1R1NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174542-A1 HETEROCYCLIC ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174542-A1 HETEROCYCLIC ANTIVIRAL AGENTS ACE, SARS1, ACE2 TAS1R3 3749/4885TAS1R1 2985/4885NPC1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.